DFS in this study was compared with that in the chemoradiotherapy arm of the RTOG-@ trial ( Phase III Intergroup Trial of Surgery Followed by Radiotherapy Versus Radiochemotherapy for Resectable High Risk Squamous Cell Carcinoma of the Head and Neck ) , which had a hazard ratio of @ for the cisplatin arm versus control ( P = @ ) and @ for the docetaxel arm versus control ( P = @ ) , reflecting absolute improvement in @-year DFS of @ % and @ % , respectively .